ArticleAIDS research and therapy2026
Effect of dolutegravir-based antiretroviral therapy transition on body mass index in adolescents living with HIV: secondary analysis of data from the ANRS 12225 Pediacam III cohort in Cameroon.
Article in AIDS research and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDolutegravir (DTG) is widely used in people living with HIV, but its potential association with weight gain remains insufficiently documented in adolescents. This study assessed the effect of transitioning to a DTG-based regimen on body mass index (BMI) in adolescents living with HIV (ALHIV) in Cameroon.
methodsData prospectively collected between 2020 and 2024 from the ANRS 12,225-Pediacam III cohort were retrospectively analyzed. The analysis included 105 ALHIV who switched to DTG (HI-DTG), 18 ALHIV who did not (HI-nDTG), and 180 HIV-uninfected adolescents born to HIV-positive mothers (HEU, n = 79) or to HIV-negative mothers (HUU, n = 101). Body mass index (BMI) trajectories and levels were compared across groups using linear mixed-effects models, as well as before and after the DTG transition within the HI-DTG group.
resultsThe median age was 11.5 years (IQR:11.0-12.5), which significant differences between groups. Overall, 51.6% were female. The median follow-up on DTG was 2.6 years (IQR:2.0-3.2). BMI trajectories differed across groups (p = 0.045) after adjustment for sex, age, baseline BMI z-score, household income, and interaction terms. Compared with HI-nDTG as the reference group, the HI-DTG group showed a modest but significant greater annual increase in BMI (0.32 kg/m²/year; 95% CI: 0.03-0.62; p = 0.03), with no differences observed for HEU or HUU. Baseline BMI z-score, household income, and female sex were more strongly associated with BMI over time than DTG use. Within the HI-DTG group, a mean annual increase of 0.19 kg/m²/year was observed after switching to DTG.
conclusionSwitching to DTG was associated with an increase in BMI among ALHIV. These findings underscore the need for close metabolic monitoring to prevent long-term cardiometabolic complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.